Should I buy CRISPR Therapeutics stock in 2025? – NZ Edition

What is CRISPR Therapeutics?

How much is the CRISPR Therapeutics stock?

The price of CRISPR Therapeutics stock is falling this week. Currently trading at USD 36.78, the stock has dipped by 1.20% over the last 24 hours and is down 0.22% for the week. The company's market capitalisation stands at USD 3.18 billion, with an average three-month trading volume of 2.03 million shares. As CRISPR Therapeutics remains unprofitable, its P/E ratio is not applicable, and it does not pay a dividend; the stock's beta is 1.87, reflecting notable volatility relative to the market. Due to these sharp price swings, investors in New Zealand should be mindful of the heightened risk and growth potential associated with biotech innovation.

Our full analysis on the CRISPR Therapeutics stock

Having conducted a rigorous review of CRISPR Therapeutics’ latest quarterly results, examined the stock’s three-year price dynamics, and synthesized multi-source analysis (including financial ratios, technical indicators, market data, and competitor benchmarking) using our proprietary quant models, a compelling picture emerges. This systematic approach sharpens our lens on both the company’s intrinsic strengths and its market context. So, why might CRISPR Therapeutics present itself once again as an exceptional strategic entry point into the gene-editing biotechnology sector as we look ahead to 2025?

Recent Performance and Market Context

CRISPR Therapeutics AG (NASDAQ: CRSP), a global leader in gene editing, currently trades at USD 36.78 as of 30 May 2025, reflecting a modest intraday decline of 1.2%. Over the past six months and year, the stock has experienced declines of -28.1% and -31.7% respectively, largely attributable to sector rotation, broader biotech volatility, and a recalibration of high-growth valuations. However, this retracement places the stock near its multi-year technical base, a zone frequently associated with long-term accumulation.

Importantly, recent news flow has tilted positively:

• Significant partnerships: The May 2025 strategic collaboration with Sirius Therapeutics for siRNA therapies underscores CRISPR’s commitment to broadening its innovation platform.
• Positive clinical updates: Fresh data from the phase 1 trial of CTX310 (targeting ANGPTL3 for cardiovascular conditions) reveals promising efficacy, significantly boosting future commercial prospects.
• Regulatory milestones: Approval and commercialization of CASGEVY—the first CRISPR-based gene-editing therapy for sickle cell disease and beta-thalassemia—set a new standard in advanced therapeutics.

The sectoral backdrop remains favourable. Global biotech investment has rebounded as risk appetite returns, notably in breakthrough segments like gene editing. Regulatory adaptation, growing precision-medicine demand, and demographic tailwinds reinforce the long-term thesis. For New Zealand-based investors, CRISPR’s strategic positioning and proven innovation in key therapeutic spaces may increasingly align with themes of sustainable health investment.

Technical Analysis

On the technical front, CRSP’s indicators reflect both near-term pressure and the potential for medium-term reversal:

• Relative Strength Index (RSI 14): At 49.39, the RSI signals a neutral momentum, emphasising a market in equilibrium—not yet oversold nor overbought.
• MACD: The marginally negative MACD (-0.03) is consistent with a recent sell signal, but the proximity to neutrality suggests a possible inflection point if renewed buying interest emerges.
• Moving averages: The stock is currently trading below its 20-day (USD 37.05), 50-day (USD 37.29), 100-day (USD 40.11), and 200-day (USD 43.70) simple moving averages. While typically a bearish structure, this also historically coincides with support-building and substantial future rebounds in high-growth biotech names.

Key support is observed at USD 35.38, the recent daily low, which has held firm amid broader sector risk-off moves. Near-term resistance is at USD 37.41, above which a breakout could catalyse further interest. Given that CRSP is trading close to a critical long-term technical floor, a confluence of technical and fundamental catalysts could drive a constructive reversal, especially as positive developments materialise.

Fundamental Analysis

Fundamentals for CRISPR Therapeutics showcase undeniable growth drivers and resilience, even as the income statement reflects a loss-making profile typical of innovative biotechs at this stage:

• Revenue: Q1 2025 revenue of USD 0.9 million represents a robust +71% YoY increase. Though absolute figures are modest, this uptrend echoes the early stages of commercialisation, expected to accelerate as approvals scale.
• Profitability: The Q1 net loss expanded to USD 136 million, or -USD 1.58 per share (below consensus). However, this reflects stepped-up R&D investment, clinical trial expansion, and infrastructure scaling—all prerequisites for sustainable long-term value.
• Valuation: CRSP remains without a publishable P/E due to negative earnings, yet consensus price targets anchor around USD 81.83, implying ~120% upside from present levels; analysts’ average targets between USD 68.65–82.32 reinforce this view. The price/sales ratio is elevated but consistent with first-in-class innovation in biotech, where global addressable markets are massive once approvals land.
• Structural strengths: CRISPR’s leadership in CRISPR/Cas9 technology, a diversified and growing therapeutic pipeline, a cash reserve of USD 1.86 billion, and world-class partnerships (notably with Vertex Pharmaceuticals) all underscore robust competitive advantages. The brand is synonymous with gene-editing innovation, further de-risked by alliances and external buy-in.

Volume and Liquidity

Brian market participation bolsters the investment case. With an average daily volume of 2.025 million shares over the past 65 days, liquidity is more than ample, allowing efficient entry and exit for institutional and retail investors alike. Market capitalisation stands at USD 3.18 billion, signposting a liquid and investable mid-cap. Furthermore, the free float is sufficiently dispersed to support dynamic price discovery and limit dramatic illiquidity swings, a critical attribute in high-volatility biotech.

Sustained trading activity at current levels typically signals investor confidence and growing interest, particularly as the market re-evaluates oversold segments with powerful new product cycles and clinical catalysts.

Catalysts and Positive Outlook

CRISPR Therapeutics is entering a phase rich in value-creating events:

• Commercial expansion: CASGEVY rollout is scaling into new geographies; additional regulatory approvals and reimbursement milestones are highly probable in the coming quarters.
• Pipeline progression: Advanced CAR-T programmes (CTX112, CTX131) address large unmet needs in oncology, while novel in vivo therapies (CTX310, CTX320) target major cardiovascular indications. Diabetes type 1 efforts (CTX211) add further breadth.
• Partnerships and innovation: Strong working ties with Sirius Therapeutics, Vertex, and Nkarta reinforce both innovation and commercialisation heft. The positive readout of CTX310 trial data further validates the in-house platform.
• ESG and technology leadership: CRISPR’s work aligns with the global shift towards sustainable, precision-focused medicine, with implications for long-term global healthcare spending and patient outcomes.
• Sector tailwinds: Continued advancements in gene-editing regulation, surging healthcare demand, and global urgency for disruptive therapies collectively foster a favourable upward environment, particularly in light of New Zealand’s growing interest in medical innovation investments.

Investment Strategies

For New Zealand-based investors and global participants alike, CRISPR Therapeutics offers several attractive potential strategies:

• Short term: Tactical positions may focus on accumulation near present support (~USD 35–36), targeting a technical bounce off oversold conditions and momentum swings as catalysts approach.
• Medium term: Investors might view the current price consolidation and probable clinical/regulatory newsflow (e.g., CASGEVY launches, pipeline updates) as justifying a hold through 2025, riding both sentiment recovery and milestone-driven advances.
• Long term: The secular opportunity embedded in gene editing, CRISPR’s robust pipeline, and its cross-therapeutic expansion suggest this could be a core holding for diversified growth-focused portfolios with a multi-year horizon. Ideal entry points cluster at technical lows or preceding known catalyst events—current valuations and anticipated milestones align with this pattern.
• Risk management: Given high volatility (beta 1.87), employing disciplined position sizing and considering portfolio context is recommended for optimal exposure.

Is it the Right Time to Buy CRISPR Therapeutics?

To summarise, CRISPR Therapeutics stands out for:

• Its leadership and innovation in CRISPR/Cas9 gene editing.
• A pipeline that is both diverse and advancing rapidly, underpinned by clinical and commercial milestones.
• Financial resilience, with a substantial USD 1.86 billion cash position to weather volatility and support growth.
• Catalysts in the form of further CASGEVY commercialisation, pipeline data, and global regulatory expansion.
• A rare average analyst price target nearly double the current share price—consensus bullishness that is unusual at this market cap and technological inflection.

Technical pressures have reset valuations to levels that often precede a structural upturn, especially as sector sentiment improves and real, revenue-generating products come to market. For New Zealand investors seeking exposure to next-generation biotechnology with transformational potential, CRISPR Therapeutics appears to represent an excellent opportunity for serious consideration, supported by fundamentals, liquidity, and a clear innovation edge.

In short, while the journey may remain volatile, the fundamental story and forward-looking catalysts suggest CRISPR Therapeutics may be entering a new bullish phase—one that forward-thinking investors will not want to overlook as the gene-editing revolution accelerates.

How to buy CRISPR Therapeutics stock in New Zealand?

Buying CRISPR Therapeutics stock online as an NZ investor is both simple and secure when using a regulated broker. You can either purchase shares directly (“spot buying”) to enjoy physical ownership or trade price movements via Contracts for Difference (CFDs) for more flexibility. Each approach offers its own benefits in terms of cost, leverage, and risk. Selecting the right method and broker is key—see our in-depth broker comparison further down this page to help you find the most suitable platform for your goals.

Spot Buying

A cash purchase means you acquire real CRISPR Therapeutics (NASDAQ: CRSP) shares and become a partial owner of the company, with the right to hold, sell, or transfer your stake at any time. You usually pay a fixed commission per order—most NZ brokers charge between NZD $5 and $15 per trade.

Important example

Example: Suppose the CRISPR Therapeutics share price is USD $36.78 (about NZD $60). With a NZD $1,000 investment and a typical NZD $5 brokerage fee, you can buy around 16 shares (as NZD $995 / $60 ≈ 16).

• ✔️ Gain scenario: If the share price rises by 10%, your holdings are now worth NZD $1,100.

Result: That’s a NZD $100 gross gain, or +10% on your investment (excluding FX effects and taxes).

Trading via CFD

A CFD (Contract for Difference) lets you speculate on the price movement of CRISPR Therapeutics shares without owning the underlying stock. With CFDs, you pay a spread (the broker’s margin between buy/sell price) and may incur overnight financing fees if you hold positions beyond a day.

Important example

Example: With NZD $1,000 and 5x leverage, you open a CFD position worth NZD $5,000 exposure to CRSP.

• ✔️ Gain scenario: If CRSP rises by 8%, your position gains 8% × 5 = 40% return.

Result: That’s a NZD $400 gain on your original NZD $1,000 deposit (not counting fees), showing the powerful effect of leverage—but note, risks are also magnified.

Final Advice

Before investing, it’s wise to compare broker fees, trading platforms, and risk management tools. Your best option depends on your investment profile: spot buying suits buy-and-hold investors seeking ownership, while CFDs suit active traders who want flexibility and leverage. Explore our broker comparison below to find the right fit for your needs, and remember—prudent choices are the foundation for successful investing.

Our 7 tips for buying CRISPR Therapeutics stock

The latest news about CRISPR Therapeutics

CRISPR Therapeutics has secured positive Phase 1 data for CTX310 targeting ANGPTL3, marking clinical progress. In the last week, CRISPR Therapeutics released encouraging results from its Phase 1 trial for CTX310, an in vivo gene editing candidate targeting ANGPTL3 to address cardiovascular diseases. This early positive safety and efficacy signal strengthens CRISPR's innovation credentials and pipeline credibility, a critical aspect for biotech-focused investors in New Zealand seeking exposure to advanced therapeutics under development. Such clinical milestones are closely monitored by life sciences investors and may bolster confidence in CRISPR's longer-term value proposition, even amid short-term volatility.

Collaboration with Sirius Therapeutics announced in May 2025 expands RNA therapeutics capabilities and future revenue opportunities. The company entered into a strategic partnership with Sirius Therapeutics to jointly develop next-generation siRNA-based therapies. This move diversifies CRISPR's technology base beyond its core gene editing focus, potentially opening up access to new therapeutic classes and licensing income streams. For New Zealand investors and fund managers, this kind of pipeline diversification is vital given the sector's risk profile, and collaborative innovation could pave the way for the company's entries into broader global and Asia-Pacific markets in the medium term.

CASGEVY, the world’s first approved CRISPR gene-editing therapy, is progressing through early commercial rollout and expansion plans in new markets. Having secured first-in-class regulatory approvals for CASGEVY in sickle cell disease and beta-thalassemia, CRISPR Therapeutics is now moving forward with its commercialization strategy. While not yet available in New Zealand, the approval trajectory in key regions is closely followed by local healthcare stakeholders and biotechnology analysts. Rapid uptake or successful market launches abroad signal increasing acceptance of gene-editing therapies, and any future regulatory engagement in Australasia could directly impact local patient access and pharmaceutical market dynamics.

Despite recent market declines, analyst consensus remains firmly positive, with a price target suggesting substantial upside potential. Over the last week, CRISPR Therapeutics’ share price saw only minor movement (-0.22%), but the consensus analyst price target remains firmly above current levels—averaging $81.83, more than double the prevailing price. With 29 analysts covering the stock and advocating a buy recommendation, this expert optimism is notable for New Zealand portfolio managers benchmarking international biotech holdings. The current sentiment, despite near-term underperformance, underscores belief in the company’s long-term technological and commercial value.

CRISPR Therapeutics maintains a robust financial profile, supporting sustained R&D and global expansion ambitions. The company reported a strong cash position of $1.86 billion at the end of Q1 2025, ensuring business continuity and supporting its diverse portfolio through costly phases of development. This financial stability is particularly important for New Zealand institutional investors who prioritize resilience and risk mitigation in the volatile life sciences sector. Ongoing R&D investments, underpinned by this solid treasury, further reinforce CRISPR’s ability to weather short-term market challenges and accelerate later-stage and commercial programs worldwide.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.